In the latest and most ambitious attempt to create a new global pharma with one foot in China and one in the West, Ascletis Inc. has launched with a hybrid drug development model that has attracted $100 million in committed funding
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.
Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.
The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.
